Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...
By Blake Brittain April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, ...
Zacks Investment Research on MSN
Moderna (MRNA) may report negative earnings: Know the trend ahead of next week's release
The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
After more than half a century of mandatory vaccination, the U.S. military will no longer require all American troops to get ...
A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...
A new effort to prepare for future avian influenza outbreaks is moving forward, despite a major funding setback.
April 21 (Reuters) - Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the ...
Moderna stock gains as the company begins dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results